Evaluation of factors associated with vertical HIV-1 transmission

Article in Jornal de pediatria · June 2015
DOI: 10.1016/j.jped.2014.12.005

CITATION
1

READS
72

7 authors, including:

- Rubens Cãurio Lobato
  Universidade Federal do Rio Grande (FURG)
  9 PUBLICATIONS  13 CITATIONS
  SEE PROFILE

- Carla Vitola Gonçalves
  Universidade Federal do Rio Grande (FURG)
  34 PUBLICATIONS  158 CITATIONS
  SEE PROFILE

- Vanusa Pousada da Hora
  Universidade Federal do Rio Grande (FURG)
  12 PUBLICATIONS  171 CITATIONS
  SEE PROFILE

All in-text references underlined in blue are linked to publications on ResearchGate, letting you access and read them immediately.
Evaluation of factors associated with vertical transmission of HIV-1 in fourteen years of a referral center in Southern Brazil

Avaliação dos fatores associados à transmissão vertical do HIV-1 em quatorze anos de um centro de referência no Sul do Brasil

Matheus Costa da Rosa\textsuperscript{a}, Rubens Cauro Lobato\textsuperscript{b}, Carla Vitola Gonçalves\textsuperscript{c}, Naylâ M. Oliveira da Silva\textsuperscript{d}, Maria F. Martinez Barra\textsuperscript{d}, Ana M. Barral de Martinez\textsuperscript{e}, Vanusa P. da Hora\textsuperscript{f,*}

\textsuperscript{a} Desenvolvimento do projeto e Autor do artigo, Universidade Federal do Rio Grande (FURG), Brazil
\textsuperscript{b} Apoio técnico e análise dos dados, Universidade Federal do Rio Grande (FURG), Brazil
\textsuperscript{c} Análise dos dados e revisão do artigo, Universidade Federal do Rio Grande (FURG), Brazil
\textsuperscript{d} Apoio técnico, Universidade Federal do Rio Grande (FURG), Brazil
\textsuperscript{e} Co-orientação do projeto e revisão do artigo, Universidade Federal do Rio Grande (FURG), Brazil
\textsuperscript{f} Orientação do estudo e revisão do artigo, Universidade Federal do Rio Grande (FURG), Brazil

Received 22 October 2014; accepted 22 December 2014

**KEYWORDS**

Human immunodeficiency virus type 1; Vertical infection transmission; Pregnant woman

**Abstract**

Aim: To compare the prevalence and factors associated with vertical transmission of HIV-1 among pregnant women treated in the periods of 1998–2004 and 2005–2011 in a reference service for the care of HIV-infected patients in southern Brazil.

Methods: A descriptive and analytical study which used the databases of laboratories of Viral Load and CD4 National Laboratory Network of STD/AIDS, Ministry of Health. HIV-1 infected pregnant women were selected following an active search for clinical information and obstetric and neonatal data from their medical records between the years 1998 and 2011.

Results: 102 pregnant women were analyzed between 1998 and 2004 and 251 in the period 2005–2011 totaling 353 children born to pregnant women with HIV-1. It was observed that vertical transmission was 11.8% between 1998 and 2004 and 3.2% between 2005 and 2011 (p < 0.001). The increased use of antiretroviral drugs (p = 0.02), the decrease in viral load (p < 0.001) and

\(0.001\)
time of rupture of membranes lower than 4 h (p < 0.001) were associated with the decrease of vertical transmission factors when comparing the two periods.

Conclusion: It was observed a decrease in the rate of vertical transmission in recent years. According to the studied variables, it is suggested that the risk factors for vertical transmission of HIV-1 were absence of antiretroviral therapy, high viral load of pregnant women and the breakthrough time greater than 4 h membranes.

© 2015 Sociedade Brasileira de Pediatria. Published by Elsevier Editora Ltda. All rights reserved.

Introduction

The mother-to-child transmission (MTCT) of human immunodeficiency virus type 1 can occur during three major periods: in utero, at birth or during breastfeeding. The HIV-1 can be transmitted intrauterine through transplacental cellular transport, through a progressive infection of the placenta’s trophoblasts until the virus reach the fetal circulation or due ruptures in the placental barrier followed by microtransfusions that occur from mother to child. The transmission during delivery occurs through the contact of the fetus with mother’s infected secretions while passing through the birth canal, through ascending infection from vagina to fetal membranes and amniotic fluid or through absorption in the neonatal digestive tract. In the postpartum period, the main form of transmission is the breastfeeding.

The vertical transmission route of HIV-1 can be influenced by several factors such as the delivery mode, the use of antiretroviral therapy, oral inflammations of newborn, prematurity and high maternal viral load. Besides these factors, the viral genetic diversity seems to play an important role in vertical transmission.

The epidemic of acquired immunodeficiency syndrome (AIDS) is found in process of stabilization, however it still presents high rates of transmission, especially among women, which characterizes the feminization of the disease. Therefore, it becomes important to understand the epidemiological profile of pregnant women and, this way, of MTCT, since the changes in prevalence depend on factors such as the use of antiretrovirals and the adherence to prenatal care for pregnant women. These and other factors may lead to a fall in MTCT, thereby facilitating the adoption of preventive measures more effective. In Brazil from 1980 to June 2013 estimated that 718.230 people are living with HIV/AIDS. According to the Brazilian epidemiological bulletin of 2013, analyzing information from 2010, the prevalence of HIV infection in pregnant women was 0.38%. Vertical transmission has become a major challenge to public health, epidemiological data show that 80% of HIV cases in children under thirteen years old had MTCT as the form of transmission.

Due to the increasing number of infected pregnant women, actions as the development of governmental programs and the monitoring of pregnant women were implemented since 2000 in Brazil, infected women and exposed child have become a compulsory reporting. According Sinan (Medical Care National System), from 2000 to 2013 were reported 77.066 cases of HIV in pregnant women, the South region of Brazil is in second place with 31,3% of cases, behind only the Southeast region (41.7%) and followed by the Northeast (14.9%), North (6.3%) and Midwest regions (5.7%). Comparing the detection rate of AIDS in children under five years (indicator used in Brazil to monitor the vertical transmission of HIV) between 2012 and 2003, it had a reduction of 35.8%.

This study aimed to compare the prevalence and factors associated with vertical transmission of HIV-1 among women treated in the periods from 1998 to 2004 and from 2005 to 2011 in a reference service for the care of HIV-infected patients in southern Brazil located at the University Hospital of Federal University of Rio Grande (HU-FURG), in the city of Rio Grande – RS.

Methodology

A descriptive and an analytic study were conducted, including 102 newborns from HIV-1 positive pregnant women in the period 1998–2004 and 251in the period 2005–2011, a total amount of 353 births.

Despite of development of Brazilian governmental programs and monitoring of pregnant women were implemented in 2000, the health care to HIV patient began in the University Hospital Dr. Miguel Riet Correa Jr – FURG in 1994, due testing and subsequent observation of the high incidence of cases in the region. Such attention was ruled from normative of the Brazilian Ministry of Health and subsequently every care protocols met as such recommendations. Due changes, such as the higher prevalence of viral subtype C and the difference of the therapeutic and pharmacological model of the patient with HIV referenced in different analyzed periods, it was decided to stratify the data to become viable the analyzes. Moreover, it could report the effectiveness of care recommended by Brazilian Ministry of Health.

Since 1998, all pregnant women attended at Dr. Miguel Riet Correa Jr. University Hospital of Federal University of Rio Grande (HU-FURG) were subjected to HIV/AIDS tests as recommended by guidelines from Brazilian Ministry of Health. Pregnant women that presented two positive serologic tests and one confirmation test or two consecutive tests with detectable viral load were classified as infected by HIV. The mothers signed an informed consent to participate in this research and this study was approved by FURG’s Ethical Committee in Health Research (23116001368/2003-44).

The outcome was the MTCT of HIV-1 in newborns and the studied variables were: use of highly active antiretroviral therapy – HAART – (Biovir + Kaletra) during pregnancy, CD4+ T cells amount in the last three months of pregnancy,
Table 1  Comparison of factors associated with mother-to-child HIV-1 transmission between the periods 1998 and 2004 and 2005–2011 in a reference service.

<table>
<thead>
<tr>
<th>Period</th>
<th>Membrane rupture times</th>
<th>p-value</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>N &gt;4 h</td>
<td>%</td>
</tr>
<tr>
<td>1998–2004</td>
<td>102</td>
<td>81</td>
</tr>
<tr>
<td>2005–2011</td>
<td>251</td>
<td>27</td>
</tr>
<tr>
<td>Total</td>
<td>353</td>
<td>108</td>
</tr>
</tbody>
</table>

Delivery mode 0.67

<table>
<thead>
<tr>
<th>Period</th>
<th>Cesarean</th>
<th>Normal</th>
<th>%</th>
<th>%</th>
</tr>
</thead>
<tbody>
<tr>
<td>1998–2004</td>
<td>102</td>
<td>39</td>
<td>38.2</td>
<td>63</td>
</tr>
<tr>
<td>2005–2011</td>
<td>251</td>
<td>90</td>
<td>35.8</td>
<td>161</td>
</tr>
<tr>
<td>Total</td>
<td>353</td>
<td>129</td>
<td>36.5</td>
<td>224</td>
</tr>
</tbody>
</table>

Mother-to-child transmission <0.001

<table>
<thead>
<tr>
<th>Period</th>
<th>HIV+</th>
<th>HIV−</th>
<th>%</th>
<th>%</th>
</tr>
</thead>
<tbody>
<tr>
<td>1998–2004</td>
<td>102</td>
<td>12</td>
<td>11.8</td>
<td>90</td>
</tr>
<tr>
<td>2005–2011</td>
<td>251</td>
<td>8</td>
<td>3.2</td>
<td>243</td>
</tr>
<tr>
<td>Total</td>
<td>353</td>
<td>20</td>
<td>5.7</td>
<td>333</td>
</tr>
</tbody>
</table>

Antiretroviral therapy during pregnancy 0.02

<table>
<thead>
<tr>
<th>Period</th>
<th>Incomplete</th>
<th>Complete</th>
<th>%</th>
<th>%</th>
</tr>
</thead>
<tbody>
<tr>
<td>1998–2004</td>
<td>102</td>
<td>40</td>
<td>39.3</td>
<td>62</td>
</tr>
<tr>
<td>2005–2011</td>
<td>251</td>
<td>67</td>
<td>26.7</td>
<td>184</td>
</tr>
<tr>
<td>Total</td>
<td>353</td>
<td>107</td>
<td>30.3</td>
<td>246</td>
</tr>
</tbody>
</table>

T CD4+ cell amount

<table>
<thead>
<tr>
<th>Period</th>
<th>cell 0–199</th>
<th>cell 200–499</th>
<th>cell &gt;500</th>
<th>%</th>
<th>%</th>
<th>%</th>
</tr>
</thead>
<tbody>
<tr>
<td>1998–2004</td>
<td>95</td>
<td>18</td>
<td>18.9</td>
<td>50</td>
<td>52.6</td>
<td>27</td>
</tr>
<tr>
<td>2005–2011</td>
<td>251</td>
<td>13</td>
<td>5.2</td>
<td>94</td>
<td>37.5</td>
<td>144</td>
</tr>
<tr>
<td>p-value</td>
<td>&lt;0.001</td>
<td>&lt;0.001</td>
<td>1.00</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Maternal viral load - Log^{10}

<table>
<thead>
<tr>
<th>Period</th>
<th>0–2.99</th>
<th>3.0–3.99</th>
<th>4.0–4.99</th>
<th>≥5</th>
<th>%</th>
<th>%</th>
</tr>
</thead>
<tbody>
<tr>
<td>1998–2004</td>
<td>95</td>
<td>27</td>
<td>28.4</td>
<td>23</td>
<td>24.2</td>
<td>35</td>
</tr>
<tr>
<td>2005–2011</td>
<td>251</td>
<td>173</td>
<td>68.9</td>
<td>49</td>
<td>19.5</td>
<td>26</td>
</tr>
<tr>
<td>p-value</td>
<td>&lt;0.001</td>
<td>&lt;0.001</td>
<td>&lt;0.001</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Children gender 0.68

<table>
<thead>
<tr>
<th>Period</th>
<th>Male</th>
<th>%</th>
<th>Female</th>
<th>%</th>
</tr>
</thead>
<tbody>
<tr>
<td>1998–2004</td>
<td>102</td>
<td>54</td>
<td>52.9</td>
<td>48</td>
</tr>
<tr>
<td>2005–2011</td>
<td>251</td>
<td>127</td>
<td>50.5</td>
<td>124</td>
</tr>
<tr>
<td>Total</td>
<td>353</td>
<td>181</td>
<td>51.3</td>
<td>172</td>
</tr>
</tbody>
</table>

pregnant women viral load, delivery mode, breakthrough time and newborns weight (Kg) after delivery. The use of antiretroviral therapy was classified as: (a) Complete – when the mother received antiretrovirals during pregnancy and in the moment of delivery as well as the newborn; and, (b) Incomplete – when at least one of the three procedures were conducted or when the mother did not use antiretroviral. Socio-demographic variables were not standardized between these periods. So it was not possible to perform the demographic profile of the population in this study (Table 1).

The data was analyzed using Stata version 8.0 statistical software (StataCorp, CollegeStation, TX). An analytical descriptive analysis of numerical variables was performed according to the studied periods, which were presented by their frequencies, mean values, standard deviation and a significant p value of 0.05 of a two-tailed test.
Results

In this study, were analyzed 353 children born from HIV-1 positive pregnant women between the years 1998 and 2011, attended at HU-FURG in the city of Rio Grande/RS.

This study showed that the rates of mother-to-child transmission obtained between the years 1998 and 2004 and 2005 to 2011 fell significantly ($p < 0.001$) from 11.8% to 3.2% respectively. It becomes interesting to observe the results in different periods, in which the transmission rate between the years 1998 and 2000 was 11.8%, from 2001 to 2004 the rate was 7.7%, from 2005 to 2008 the rate was 2.7% and from 2009 to 2011 the transmission rate was 2.9% (Fig. 1).

For the analyzed variables in both studied periods, could be observed that between the periods from 1998 to 2004, 79.4% of the pregnant women had a membrane rupture time longer than 4h. In contrast, for the period between 2005 and 2011, only 10.8% of pregnant women had a membrane rupture time longer than 4 hours ($p < 0.001$).

There was no significant difference in the mode of delivery between the two studied periods, neither in the average weight of newborns after delivery. The use of antiretroviral therapy throughout the gestational period was done by 69.7% of the pregnant women. Between the years 1998 and 2004, 60.7% of pregnant women adhered to HAART and, between the years 2005 and 2011, the adherence rate was 73.3% ($p < 0.02$) suggesting that the adhesion to the antiretroviral therapy by pregnant women appears to be an important factor in the reduction of mother-to-child transmission. It was considered complete use of ART when mothers reported having used the drug during the antenatal period, at delivery and her newborn have received prophylaxis with oral suspension of Zidovudine (AZT) for six weeks after delivery. The use of injecting AZT and oral AZT was checked with the drug dispensing control spreadsheets during hospitalizations of the patient, according to the protocol established by Health Ministry of Brazil. Since 1998, the PMTCT attention was performed following the recommendation to AZT monotherapy. In 2001 it was recommended the triple therapy combining three ARTs, inserting the Nevirapin and Nelfinavir. In 2007, following the recommendation of the Brazilian Health Ministry, Kaletra was introduced, replacing Nelfinavir.

![Figure 1](https://example.com)  
**Figure 1** Comparison of the mother-to-child HIV-1 transmission rates between the periods from 1998 to 2011 in a reference service.

There was an increase in the CD4+ T cells amount (CD4+ T cells > 500) when comparing both studied periods. According the analyzed data, between the years 1998 and 2004, was observed a frequency of 29.4% of pregnant women with CD4+ T cells amount higher than 500. However, in the period of 2005–2011, the percentage of pregnant women with CD4+ T cells amount higher than 500 increased to 57.3% ($p < 0.001$). When analyzing the maternal viral load, can be observed that pregnant women with viral load between undetectable and log of 2.9 was 68.0% in the period of 2005–2011 and 28.4% in the period of 1998–2004 ($p < 0.001$).

Discussion

Brazil has as goal the elimination of HIV-1 vertical transmission (less than 1% of transmission) until 2015. Studies have shown that it is possible to prevent new HIV infection in children, since HIV-positive pregnant women have timely and appropriate access to prenatal care and to HAART. In the present study was observed a rate of vertical transmission of 5.7% from a total of 353 children born from seropositive mothers for HIV-1 between the years 1998 and 2011. However, it is interesting to analyze the rate of mother-to-child transmission in different periods. In this study can be noted that between the years 1998 and 2000 the MTCT rate was 11.8%, from 2001 to 2004 the rate was 7.7%, from 2005 to 2008 the rate was 2.7% and from 2009 to 2011 the MTCT rate was 2.9%, this demonstrates that the MTCT rates are relatively low when analyzes at different times. There has been a small increase in MTCT rates between the years 2005 and 2008 (2.7%) and 2009–2011(2.9%), which may be justified due to the fact that a portion of pregnant women HIV positive still do not make use of chemoprophylaxis during the pregnancy, especially drug users and currently the specific use of the illicit drug CRACK. Data showed that pharmacy records can help identify less-than-optimal adherence to treatment. Because of stabilization of values of the referenced MTCT rates not only in this study as well as in Brazil, the Brazilian Ministry of Health implemented in 2012 the use of Nevirapine (NVP) (Technical Note n. 388/2012). In Brazil has been advocating the use of AZT associated with NVP for the prevention of newborns to HIV since a recently published study demonstrated that the oral treatment with a solution containing AZT during six months associated to an oral suspension with NVP, three doses in the first week of life, significantly reduce the rate of mother-to-child transmission from pregnant women who did not use chemoprophylaxis during pregnancy.

Taking into account the aim of this study, observing the rates obtained between the years 1998 and 2004 and 2005–2011, it is noticed a drastic drop in the transmission rates from 11.8% to 3.2% respectively, result that clearly demonstrates the decline in mother-to-child transmission rates. Comparing these results with studies conducted in the same Brazilian region, a studied published in 2006 observed a MTCT rate of 11.8% in infants born between the years 1998 and 2003. Later in another study published in 2010 from the same region, was observeda MTCT rate of 4.8% between the years 2003 and 2007 and, in the present study, was observed a MTCT rate of only 2.9% when analyzed only the period from 2007 to 2011. These results clearly demonstrate that there...
was a decrease in the MTCT rates of HIV-1, which highlights
the effectiveness of the national policy and program for the
control of mother-to-child transmission.

With the approval of Law No. 9.313 on November 13, 1996,
Brazil began to rely in its legal system with one legislation
that ensures the access to antiretroviral by people living
with HIV/AIDS. Thus, Brazil became the first emerging coun-
try to provide antiretroviral therapy to patients that need
it. In 2009, the Secretary of Substitute Health Surveillance
started to use fast HIV tests in pregnant women, according
to the authority conferred by the Article 45 of the Decree
No. 6.860 of May 27, 2009.9,11 Therefore, it can be sug-
gested that these control measures had an influence in the
decine of the HIV infection rates in infants between the
studied periods, result that demonstrates the importance
of these control measures in public health services. Similar
decreases in mother-to-child transmission rates are found
in several countries that adopt control measures, especially
the use of antiretroviral therapy by HIV positive pregnant
women.16 In the present study, could be observed that
69.7% of mothers made use of antiretroviral throughout
the gestational period, suggesting a decline in the vertical trans-
mision rate. In a study published in 2011 was observed that,
from 25 seropositive children, 9% were born from mothers
that received inadequate antiretroviral therapy during preg-
nancy, a fact that occasioned a rate of only 1.7% of vertical
transmission.17

When analyzing the different periods of this study, it
can be observed that, between the years 1998 and 2004, 60.7% of
pregnant women adhered to the use of antiretroviral therapy
and, between the years 2005 and 2011, there was an
increase in pregnant women that adhered to antiretrovi-
ral therapy during pregnancy with a percentage of 73.3%.
This suggests a low viral load in pregnant women and a
decrease in vertical transmission rates between the periods
from 2005 to 2011, whereas it is only 3.2%. These results
corroborate with a previous study, which demonstrated that
the main risk factors for HIV transmission were the failure
of antiretroviral therapy, late maternal diagnosis and, con-
sequently, high viral load of pregnant women at delivery.9

The antiretroviral therapy during pregnancy is extremely
important in order to prevent vertical transmission and it
can be used during any period regardless the clinical condi-
tion in which the mother is found.15 Studies have reported
that a high viral load and a low CD4+ T cells amount during
pregnancy are significant factors for mother-to-child trans-
mision to occur.8,19

It is noteworthy that a time lower than 4 h for the
membrane rupture is extremely important to reduce
mother-to-child transmission of HIV-1.10 In this study, it can
be observed a significant decrease (p < 0.001) in rupture
time when analyzing the studied periods, since there was
a frequency of 79.4% of pregnant women who had a rupture
time higher than 4 h between the period from 1998 to
2004. In contrast, in the period 2005–2011, the frequency
was 10.8% of pregnant women who had a rupture time higher
than 4 h. The significant difference between membrane rupture
time in both studied periods is the result of the update
of care protocols for HIV pregnant women. In 2004 started
the encouragement of HIV testing during prenatal care and
proper implementation of prevention actions of vertical
transmission of HIV, with the first published protocol in
2007. According to the Brazilian guide for recommendations
for prophylaxis of the transmission of HIV and antiretrovi-
ral therapy in pregnant women, the active management
of labor should occur to prevent prolonged membrane rupture
time, once the less time decreases the risk of vertical
transmission.9

Despite of the effort to reduce the MTCT, the residual
risk of that transmission is still relatively high in compari-
son of what it is observed elsewhere in the HAART area.3,11
The fact that the Southern of Brazil is characterized to have
more prevalence of HIV-1 subtype C, which is intrauter-
ine more transmissible,8 it can help to explain the rate of
MTCT found in the present study. Beyond this fact, late
entrance and lack adherence to prenatal care, especially in
drug users, favor the MTCT. A study showed that low prena-
tal screening coverage of maternal HIV infection, impairing
maternal treatment or prophylaxis; and the incorrect use
of the rapid screening test at admission for delivery are
impediments to the effective reduction of MTCT of HIV.11

For the attention to pregnant women with low adherence
to prenatal be expanded in the region of this study, especially
those drug users, the referral service of University Hospital
Dr Miguel Riet Correa of FURG/Rio Grande conducts active
search of women in favor of the effectiveness of compliance
with care protocols to prenatal care as recommended by the
Brazilian Ministry of Health.

Therefore, this study may suggest that the increase of
antiretroviral therapy during pregnancy, the time for mem-
brane rupture lower than 4 h and low viral load contributed
to the decline of mother-to-child HIV-1 transmission in both
studied periods. These results agree with the data obtained
in the literature.2,7,23 However, more studies should be
carried out to establish which factors are involved in mother-
to-child transmission.

Conflicts of interest

The authors declare no conflicts of interest.

Uncited reference

12.

Acknowledgments

To the Laboratory of AIDS Support, the infectious diseases
doctors and obstetricians from the Service AIDS/HIV of Uni-
versity Hospital Dr Miguel Riet Correa of FURG and the
Brazilian Ministry of Health.

References

1. Renjifo B, Gilbert P, Chaplin B, et al. Preferential in-utero trans-
mision of HIV-1 subtype C as compared to HIV-1 subtype A or
2. Newell M. Mechanisms and timing of mother-to-child transmis-
ciency virus type 1 and diseases stage among women in Nairobi,


